JPRN-UMIN000016543已完成未知
Evaluation of the Usefulness of Adalimumab in Patients with Psoriatic arthritis - Evaluation of the Usefulness of Adalimumab for Psoriatic arthritis
agoya City University Graduate School of Medical Sciences, Department of Geriatric and Environmental Dermatology0 个研究点目标入组 50 人开始时间: 2015年2月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with other active skin disease possibly disturbing evaluation of psoriasis-related skin symptoms (2)Patients having received intraarticular or intratendinous injection of steroid with 4 weeks before the start of this study (3)Patients having received biological preparations during the period specified below: Infliximab: within 8 weeks before the start of this study Ustekinumab: within 12 weeks before the start of this study Other biological preparations (including drugs on clinical trial): within 24 weeks before the start of this study (4)Patients receiving ultraviolet ray therapy or using ciclosporin or etretinate at the start of this study of this study (5)Patients with serious infection (sepsis, etc.) (6)Patients with active tuberculosis (7)Patients with a history of hypersensitivity to any component of the study drug (8)Patients with demyelinating disease (multiple sclerosis, etc.) or its history (9)Patients with congestive heart failure (10)Other patients judged by the investigator or the like as inappropriate for this study
研究者
相似试验
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-BEAbbott GmbH & Co. KG1,200
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-NOAbbott Laboratories1,200
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-GBAbbott GmbH & Co. KG1,200
进行中（未招募）
1 期
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-DKAbbott GmbH & Co. KG1,200
进行中（未招募）
不适用
Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis – An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-alpha Inhibitors. - RHAPSODYActive Ankylosing SpondylitisEUCTR2005-004826-21-SEAbbott GmbH & Co. KG1,200